| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/16/2004 | EP1427818A2 Nucleic acid molecules coding for a dextran-saccharase catalysing the synthesis of dextran with alpha 1,2-osidic sidechains |
| 06/16/2004 | EP1427817A1 Multiplication of viruses in a cell culture |
| 06/16/2004 | EP1427813A2 Method for dendritic cells-based immunotherapy of tumors using combination therapy |
| 06/16/2004 | EP1427806A2 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 06/16/2004 | EP1427758A2 Compositions and methods of treating diabetes |
| 06/16/2004 | EP1427757A1 Late gestation lung genes, fragments and uses thereof |
| 06/16/2004 | EP1427756A1 Modified human growth hormone |
| 06/16/2004 | EP1427755A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 06/16/2004 | EP1427754A1 Nucleic acid and polypeptide linked to breast cancer and uses therefor |
| 06/16/2004 | EP1427753A2 Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing them and their applications |
| 06/16/2004 | EP1427750A1 Modified transferrin fusion proteins |
| 06/16/2004 | EP1427450A2 Inhibition of rna function by delivery of inhibitors to animal cells |
| 06/16/2004 | EP1427449A1 Anti-cancer agents comprising disintegrin genes and the treating methods |
| 06/16/2004 | EP1427440A2 Procede d'amelioration de la cicatrisation |
| 06/16/2004 | EP1427439A1 Gamma three protease |
| 06/16/2004 | EP1427438A2 Inflammation modulatory compound comprising an endomorphin |
| 06/16/2004 | EP1427437A1 Oxyntomodulin for preventing or treating excess weight |
| 06/16/2004 | EP1427436A2 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection |
| 06/16/2004 | EP1427435A1 Method for re-sensitizing vancomycin resistant bacteria using agents which selectively cleave a cell wall depsipeptide |
| 06/16/2004 | EP1427434A2 Anti-inflammatory agent |
| 06/16/2004 | EP1427433A1 Biodegradable implant comprising a polylactide polymer and a lh-rh analogue |
| 06/16/2004 | EP1427432A2 Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives |
| 06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
| 06/16/2004 | EP1427428A2 Apoptosis-mimicking natural vesicles and use thereof in medical treatment |
| 06/16/2004 | EP1427426A2 Gpi-anchored cytokines |
| 06/16/2004 | EP1427406A2 Modulation of stat activity |
| 06/16/2004 | EP1427405A2 Inflammation-inhibiting compounds |
| 06/16/2004 | EP1427394A1 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities |
| 06/16/2004 | EP1427391A1 Vascular occlusion solid-phase agent with immobilised platelet binding agent |
| 06/16/2004 | EP1427385A2 Medicine for preventing and treating bromidrosis |
| 06/16/2004 | EP1427383A1 Compositions and methods relating to prevention of chemotherapy-induced alopecia |
| 06/16/2004 | EP1427349A2 Interleukin-12 as a veterinary vaccine adjuvant |
| 06/16/2004 | EP1427289A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption |
| 06/16/2004 | EP1355660A4 Therapeutic modulation of the tumor inflammatory response |
| 06/16/2004 | EP1351841A4 Oil maintenance indicator |
| 06/16/2004 | EP1296706A4 Osteoclast secreted chemokine and uses thereof |
| 06/16/2004 | EP1278771A4 A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof |
| 06/16/2004 | EP1246839B1 Depsipeptide and congeners thereof for use as immunosuppressants |
| 06/16/2004 | EP1232176A4 Tumour suppressor factor |
| 06/16/2004 | EP1173194B1 Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation |
| 06/16/2004 | EP1152767B1 Method for producing anti-tumor th1 cells |
| 06/16/2004 | EP1144425B1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 06/16/2004 | EP1071806B1 Recombinant adeno-associated viral vector encoding alpha-1-antitrypsin for gene therapy |
| 06/16/2004 | EP1061947B1 Stabilized aqueous glucagon solutions comprising detergents |
| 06/16/2004 | EP1027053B1 Method of preventing nephrotoxicity caused by cyclosporins or tacrolimus |
| 06/16/2004 | EP1005540B1 Ikk-beta proteins, nucleic acids and methods |
| 06/16/2004 | EP0986381B1 Use of diterpenes like hypoestoxides for the manufacture of a medicament for immunosuppression, anticancer and antiviral treatment |
| 06/16/2004 | EP0881908B1 Use of fibroblast growth factors to stimulate bone growth |
| 06/16/2004 | EP0865499A4 Production of lysosomal enzymes in plant-based expression systems |
| 06/16/2004 | EP0847530B1 QUANTITATION OF p97 TO DIAGNOSE AND MONITOR ALZHEIMER'S DISEASE |
| 06/16/2004 | EP0722333B1 Bpi-protein-products for depressed reticuloendothelial system function |
| 06/16/2004 | EP0672133B1 TNF-alpha RIBOZYMES AND DEGRADATION RESISTANT mRNA DERIVATIVES LINKED TO TNF-alpha RIBOZYMES |
| 06/16/2004 | EP0667908B1 Soluble t-cell receptor alpha chain and derivatives used as prophylactic and therapeutic agents for autoimmune diseases |
| 06/16/2004 | CN1505640A T cell receptor Vbeta-Dbeta-Jbeta sequence and methods for its detection |
| 06/16/2004 | CN1505638A Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| 06/16/2004 | CN1505617A Peptides as met-ap2 inhibitors |
| 06/16/2004 | CN1505537A Disease prevention by reactivation of the thymus |
| 06/16/2004 | CN1505527A Combination therapy using anti-angiogenic agents and tnfa |
| 06/16/2004 | CN1505526A Compositions and methods for wt1 specific immunotherapy |
| 06/16/2004 | CN1505525A Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| 06/16/2004 | CN1505522A Stimulation of thymus for vaccination development |
| 06/16/2004 | CN1505502A Fibrate-statin combinations with reduced fed-fasted effects |
| 06/16/2004 | CN1504752A Vaughan Tristan J. |
| 06/16/2004 | CN1504573A Confluent protein capable of self-cracking into polypeptide with antibiosis and reparation function |
| 06/16/2004 | CN1504569A Chromatography purification process of viper venom blood clotting enzyme |
| 06/16/2004 | CN1504483A NF-ª—B inhibitor, preparing process thereof and application as antineoplastic medicine |
| 06/16/2004 | CN1504481A Apoptosis promoting gene BNIPL, coding albumen and uses thereof |
| 06/16/2004 | CN1504480A Endothelin receptor antagonist of tripeptide |
| 06/16/2004 | CN1504479A Bone formation stimulant, synthetic method and uses thereof |
| 06/16/2004 | CN1504476A Polynucleotide for identifying polypeptide OT3 and coding OT3 of tumor cell and uses thereof |
| 06/16/2004 | CN1504475A Polynucleotide for identifying polypeptide OT10 and coding OT10 of tumor cell and uses thereof |
| 06/16/2004 | CN1504462A Pyrimidinyl derivatives as interleukin inhibitors |
| 06/16/2004 | CN1504239A Improved carrier system for cyclosporin pharmaceutical compositions |
| 06/16/2004 | CN1504238A Medicine for treating diabetes |
| 06/16/2004 | CN1504237A Medicine composition containing alfa-interferon , adefovir and FTC |
| 06/16/2004 | CN1504236A Medicine composition containing alfa-interferon , lamivudine and adefovir |
| 06/16/2004 | CN1504235A Tie2 receptor-induced gene transfer system for treating target tumor genes |
| 06/16/2004 | CN1153780C Protein with thrombopoiesis substance activity |
| 06/16/2004 | CN1153590C Blood substitute of hemoglobin microcapsule and preparing method thereof |
| 06/16/2004 | CN1153589C Treatment of infertility and enhancement of fertilization capacity in mammalian males |
| 06/16/2004 | CN1153588C Dialysis fluid containing peptides as osmotic agents obtained from casein and bicarbonate ions as buffering agents |
| 06/16/2004 | CN1153567C Scale production method of forming microparticles |
| 06/16/2004 | CN1153563C Antioxidant preparation for buccal use |
| 06/15/2004 | US6750334 Ctla4 (cd28-like which are t lymphocyte molec) used to suppress an immune response in the subject, for example to inhibit transplantation rejection, graft versus host disease or autoimmune response |
| 06/15/2004 | US6750330 Lyophilized tubulins |
| 06/15/2004 | US6750327 Compositions and method for determining the presence of human PTTG peptide in a sample |
| 06/15/2004 | US6750325 CD3 specific recombinant antibody |
| 06/15/2004 | US6750324 Agents and methods for treatment of diseases associated with amyloid deposits of a beta in the brain such as alzheimer's disease; entail administering agents that induce a beneficial immunogenic response against the amyloid deposit |
| 06/15/2004 | US6750323 Platelet activation protein |
| 06/15/2004 | US6750321 Insulin-like growth factor agonist molecules |
| 06/15/2004 | US6750209 Advanced glycation end-product intermediaries and post-amadori inhibition |
| 06/15/2004 | US6750206 Recombinant nucleic acid vector comprising a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface |
| 06/15/2004 | US6750203 Inhibition of inductive effect of beta casein on insulin-dependent diabetes comprising administering to newborns and infants an infant formula free of beta caseins that exhibit molecular mimicry with protein glut2 |
| 06/15/2004 | US6750202 Inhibitors of procollagen c-proteinase (pcp), for treating fibrosis of the liver |
| 06/15/2004 | US6750201 Peptide which promotes binding of scupa to lm-tk- cells and thereby promotes internalization and degradation of scupa by those cells |
| 06/15/2004 | US6750199 Antimicrobial sulfonamide derivatives of lipopeptide antibiotics |
| 06/15/2004 | US6750198 Treating disorders characterized by a reduction in pigmentation comprising administering an effective amount of the protein dcoh |
| 06/15/2004 | US6750197 Activators of endothelial nitric oxide synthase |
| 06/15/2004 | US6750196 Methods of treating disorders of the eye |
| 06/15/2004 | US6750194 Administering to the subject a safe and effective amount of a vpac receptor agonist selected from the group consisting of ro 25-1553, and pacap-38 |